News coverage about Seattle Genetics (NASDAQ:SGEN) has been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Seattle Genetics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.3886543012513 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
- Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting – Business Wire (press release) (businesswire.com)
- Seattle Genetics, Inc. (SGEN) Insider Sells $599,700.00 in Stock (americanbankingnews.com)
- Market-Moving News Is on Tap for Seattle Genetics (finance.yahoo.com)
- What Analysts Recommend for United Therapeutics in November 2017 (finance.yahoo.com)
Seattle Genetics (NASDAQ SGEN) traded down $1.83 during trading hours on Tuesday, reaching $56.05. 839,848 shares of the company traded hands, compared to its average volume of 963,968. Seattle Genetics has a twelve month low of $45.31 and a twelve month high of $71.32.
SGEN has been the topic of a number of recent research reports. Jefferies Group reaffirmed a “buy” rating and set a $53.00 price target on shares of Seattle Genetics in a research report on Thursday, October 26th. Cann reaffirmed a “hold” rating on shares of Seattle Genetics in a research report on Tuesday, August 29th. Zacks Investment Research raised shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a research report on Tuesday, October 10th. Morgan Stanley raised their price target on shares of Seattle Genetics from $64.00 to $69.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 31st. Finally, Royal Bank Of Canada raised their price target on shares of Seattle Genetics from $68.00 to $69.00 and gave the stock an “outperform” rating in a research report on Monday, November 13th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Seattle Genetics has an average rating of “Hold” and an average price target of $63.53.
In related news, insider Vaughn B. Himes sold 10,000 shares of Seattle Genetics stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $59.97, for a total transaction of $599,700.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Darren S. Cline sold 5,024 shares of Seattle Genetics stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $51.94, for a total transaction of $260,946.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 178,143 shares of company stock worth $10,312,524. 34.70% of the stock is owned by corporate insiders.
About Seattle Genetics
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.